HomeAI · summaries
Storia in 5 fonti
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
FDA Approves Eli Lilly’s Weight Loss Pill Foundayo—Fewer Food And Drink Restrictions
Lilly says Foundayo was approved to treat obesity and can lead to long-term weight loss, alongside diet and exercise.
- ·
cnbc.com
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.
- ·
upi.com
FDA approves Eli Lilly's GLP-1 weight-loss pill Foundayo - UPI.com
The Food and Drug Administration on Wednesday approved Eli Lilly's pill version of a GLP-1 medication for weight loss.
- ·
usatoday.com
Eli Lilly wins approval for new weight-loss pill. What to know.
Eli Lilly's new weight-loss pill, sold under the name Foundayo, gives consumers a second option for a non-injectable GLP-1.
- ·
wired.com
FDA Approves Eli Lilly’s GLP-1 Pill
Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.
- ·
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.